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It has been estimated that as many as one mil-
lion cells die each second by apoptosis in the 
human body as part of normal tissue turnover 
(Green et al., 2009). The remnants of the dying 
cells are cleared by phagocytic cells, like mac-
rophages and DCs, with potent immunomod-
ulatory abilities. The end result is normally an 
antiinflammatory milieu and homeostasis (Savill 
et  al.,  2002).  Nevertheless,  both  exogenous 
(Torchinsky et al., 2009) and endogenous fac-
tors (Green et al., 2009) can shift the response 
to a more proinflammatory situation. Because 
an apoptotic cell can be described as a bag of 
modified self-antigens, the connection to auto-
reactive activation is quite plausible (Utz et al., 
2000). Examples of this are seen in SLE patients 
where  defects  in  clearing  apoptotic  cells  are 
linked to development of autoimmune disease 
with autoantibody production and systemic or-
gan manifestations (Gaipl et al., 2006). It has 
been shown that these patients have increased 
numbers of apoptotic cells in the circulation 
and  that  their  macrophages  have  defects  in 
clearing  apoptotic  cells  (Herrmann  et  al., 
1998; Perniok et al., 1998). Animal studies fur-
ther solidify these theories by demonstrating 
that repeated injections of syngenic apoptotic 
cells,  without  adjuvant,  lead  to  a  transient   
SLE-like phenotype (Mevorach et al., 1998). 
Collectively, these observations highlight the 
importance of proper removal of apoptotic 
cells to limit inflammation and activation of   
autoreactive lymphocytes. This also suggests 
the existence of a threshold for autoreactive 
activation dependent on factors involved in the 
removal of apoptotic cells. As the etiology of 
SLE is complex, many factors and cell types can 
be involved in setting this threshold, a thresh-
old that is needed to limit autoreactivity, while 
allowing activation against microbes in the   
vicinity of apoptosis.
The role of the CD1d-restricted NKT cell 
population has been widely studied since its 
discovery more than two decades ago (Godfrey 
and Kronenberg, 2004). This unconventional 
T cell expresses NK cell markers and a semi-
invariant T cell receptor that recognize lipid 
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Faulty activation of autoreactive B cells is a hallmark of autoimmune diseases like systemic 
lupus erythematosus (SLE). An important feature restricting activation of autoreactive  
B cells is efficient removal of apoptotic material. Mounting evidence also connects a pri-
mary defect in invariant natural killer T (iNKT) cells to autoimmune disease development. 
However, exactly how this unconventional T cell subset is involved remains to be defined. 
Here, we identify a suppressive role for iNKT cells in a model where autoantibody produc-
tion is triggered by an increased load of circulating apoptotic cells, resembling the situation 
in SLE patients. Absence or reduction of iNKT cells as well as absence of CD1d-expression 
on B cells, needed for direct iNKT–B cell interaction, leads to increased autoreactive B cell 
activation and symptoms of disease. The suppression mediated by the iNKT cells is observed 
before B cell entry into germinal centers and can be rescued by transferring iNKT cells to 
deficient mice. This links iNKT cells to handling of dying cells and identifies a novel periph-
eral tolerance checkpoint relevant for autoimmune disease. Thus, these observations  
connect two clinical observations in SLE patients previously considered to be unrelated  
and define a new target for immunotherapy.
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compared with WT mice (Fig. 1 A). No difference in preim-
mune (PI) levels were observed, although spontaneous SLE-
like disease has been observed in old J18/ mice (Sireci   
et al., 2007). These data suggest that the predisposition for 
autoimmune disease development in these mice could be 
triggered by challenging the response to apoptotic cell death. 
An increase in IgG3 anti-DNA was also seen (Fig. 1 B), indi-
cating a role for the splenic marginal zone B (MZB) cell pop-
ulation, a B cell pool known to rapidly produce IgG3 and to 
contain autoreactive clones (Enzler et al., 2006; Guinamard 
et al., 2000). In addition to DNA, several lipid autoantigens 
are described in systemic autoimmune disease (Valesini and 
Alessandri, 2005), and a significant increase in IgG reactivity 
against both cardiolipin and phosphorylcholine was seen in 
the injected NKT/ mice (Fig. 1 C). In agreement with the 
autoantibody production, a significantly increased glomeruli 
deposition of IgG immune complexes (ICs) was found in 
kidneys of the NKT/ mice (Fig. 1 D). The transient nature 
of the used model does not allow for changes related to the 
chronic phase of IC-mediated disease. Still, in the absence of 
NKT cells, lymphocyte infiltration was observed in glo-
meruli of the experimental group by hematoxylin and eosin 
(H&E) staining (Fig. 1 D).
Years of studies on autoimmune diseases have identified 
the importance for both central and peripheral tolerance. It is 
known that SLE patients have defects in checkpoints that 
normally limit autoreactive B cell development (Yurasov   
et al., 2005). Because CD1d is highly expressed on develop-
ing and mature B cells, with the highest expression found on 
the mature MZB population (Fig. S1), we examined if the 
increased autoreactive activation seen in the NKT/ mice 
could be caused by an altered B cell development and thus be 
attributed to a general effect on B cell responses. However, 
when analyzing the splenic MZB cell population with FACS 
(fluorescence activated cell sorter) in WT and the two differ-
ent NKT/ mice used, no difference was seen (Fig. 1 E). The 
same was also true for conventional/follicular B cells (FoB; 
not depicted). Furthermore, no difference was seen in the 
response to the T cell-independent type II antigen TNP-Ficoll 
(a response where the MZB cells are involved; (Guinamard 
et al., 2000), in the response to the T cell-dependent anti-
gen NP-OVA or in natural phosphorylcholine (PC) anti-
body levels (Fig. 1 F-H), suggesting functionally normal   
B cell compartments. Moreover, ex vivo stimulation of spleno-
cytes with the polyclonal activator LPS did not show any 
difference in anti-DNA response, demonstrating that the 
NKT/ mice do not have an obvious increase in autoreac-
tive B cell clones (Fig. 1 I). It has been found that iNKT cells 
can provide help for B cell activation if the strong iNKT cell 
activating ligand GalCer is presented by CD1d on the B cell 
(Barral et al., 2008; Leadbetter et al., 2008). This establishes 
that activated B cells do interact with iNKT cells via CD1d 
and, taken together with the data presented here, that the 
outcome of B – iNKT cell interaction is context and/or   
ligand dependent. Recently, an IL-10 producing CD1dhi  
B cell has been described, which could be involved in 
derivatives presented by the MHC class I–like molecule 
CD1d (Brutkiewicz, 2006). The NKT cell population can be 
further divided into the most studied type I/invariant (from 
now on called iNKT) and type II NKT cells, where the former 
expresses an invariant V14-J18 TCR chain and the latter 
uses diverse TCR, resulting in different ligand recognition 
(Rolf et al., 2008). Studies in several murine models for auto-
immune disease have identified an important regulatory role 
for the NKT cells (Wu and Van Kaer, 2009). For example, 
SLE and diabetes susceptibility loci have been shown to 
negatively control iNKT cell numbers (Esteban et al., 2003), 
and introduction of CD1d deficiency, and thereby iNKT   
cell deficiency, does worsen nephritis in the SLE prone 
(NZBxNZW)F1 mice (Yang et al., 2007). Controversy does, 
however, exist as some studies show evidence that iNKT 
cells could also be involved in driving the disease develop-
ment (Forestier et al., 2005; Takahashi and Strober, 2008). 
Human studies describe reduced numbers of iNKT cells in 
several autoimmune patient cohorts and this is, at least in 
SLE, considered a primary defect as it is seen also in family 
members without clinical symptoms (Wither et al., 2008).
Here, using a model where injections of syngenic apo-
ptotic cells trigger autoantibody production, we identify a 
novel mechanism linking iNKT cells to autoreactivity. We 
demonstrate, in vivo, a protective role for iNKT cells and that 
CD1d expression on B cells regulates autoreactive B cell acti-
vation. This regulatory CD1d-dependent checkpoint is seen 
at the pre–germinal center (GC) stage as B cells dramatically 
down-regulate CD1d when they enter GCs. Furthermore, we 
identify that iNKT cells are rapidly affected by apoptotic cell 
death of surrounding cells, shown by their decreased ability to 
produce IFN-. Collectively, this identifies the involvement 
of an iNKT cell–CD1d+ B cell axis in the antiinflammatory 
response to apoptotic cell death with potential relevance for 
autoimmune disease.
RESULTS AND DISCUSSION
Absence of iNKT cells exaggerates the activation  
of autoreactive B cells triggered by an increased load  
of apoptotic cells without affecting B cell development  
or general B cell activation
During the process of apoptosis, major changes occur in the 
lipid bilayer that makes up the cell membrane. This sends a multi-
tude of signals to surrounding cells (Huynh et al., 2002). Be-
cause NKT cells scan the body for lipid derivatives presented 
by CD1d (Brutkiewicz, 2006), we hypothesized that NKT 
cells could be involved in the immunological silence mediated 
by apoptotic cell death. To examine if a link exists between 
the handling of apoptotic cells and NKT cells in the develop-
ment of autoimmune disease, WT and two different NKT 
cell-deficient mice (NKT/) were injected with syngenic 
apoptotic cells (Mevorach et al., 1998). Both CD1d/ (needed 
for selection of both iNKT and type II NKT cells; Chen   
et al., 1997), and J18/ mice (lacking the J segment used 
by the semiinvariant iNKT cell receptor; Cui et al., 1997) 
showed  a  significantly  higher  IgG  anti-DNA  response JEM VOL. 207, May 10, 2010  945
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different NKT/ strains, one lacking iNKT cells and the 
other both iNKT and type II NKT cells, we conclude that 
(a) the absence of iNKT (type I) cells increases the autore-
active B cell response to apoptotic cells and (b) that this   
is not caused by an altered B cell development or a general   
B cell deregulation.
regulating  autoimmune  responses  (Yanaba  et  al.,  2008). 
The question was raised whether the CD1dhi B cell could 
be  involved  in  the  used  model  and  be  affected  in  the 
CD1d/ mice. However, no expansion of IL-10 produc-
ing B cells was observed in mice injected with apoptotic 
cells (Fig. S2). As a similar phenotype was seen in the two 
Figure 1.  Increased activation of autoreactive B cells in iNKT cell–deficient mice. (A) WT and NKT-deficient mice (J18/ and CD1d/) injected 
four times i.v. with syngenic apoptotic cells. Serum IgG anti-DNA response is followed preimmune (PI) to day 61. (B) IgG3 anti-DNA PI and day 33. (C) IgG 
reactivity against lipid antigens (cardiolipin and PC) PI and day 33. (D) Representative kidney histology from day 61. 10× and 100× magnification of IgG 
immune complex (IC) deposition, H&E staining, and quantification of IC deposition (score 0–3). Bars: 300 µm (low); 47 µm (high). (E) FACS plot showing 
MZB cell gating of viable CD19+ splenocytes and quantification of the MZB cells in WT and NKT/ mice. (F) IgG response to the T cell–independent type II 
antigen TNP-Ficoll in WT and NKT/ mice. (G) IgG response to the T cell–dependent antigen NP-OVA in WT and CD1d/. (H) IgM anti-PC in serum of 
untreated WT and CD1d/ mice. (I) IgG anti-DNA response after ex vivo stimulation of splenocytes with LPS for 72 h. Antibody levels (A–C and F–I) were 
measured by ELISA. Results expressed as mean ± SEM in A–C (n = 6–8), E (n = 5), F (n = 10–11), G (n = 6), I (n = 3), and individual mice and mean in D  
(n = 7–8) and H (n = 35–42). n.s., not significant. *, P < 0.05; **, P < 0.01. In A, the significance is related to the WT response. Data are representative of at 
least two independent experiments or (H) pooled from three independent experiments.946 iNKT cells in autoreactive B cell activation | Wermeling et al.
single injection of apoptotic cells (Fig. 2 A). Thus, the iNKT 
cells rapidly recognize the apoptotic cell death event.
iNKT cells are potent cytokine producers, which in many 
systems has been defined as their main function. In autoim-
mune models, a protective role for iNKT cells has often been 
attributed to a shift in their cytokine signature toward a less 
proinflammatory one (Miyamoto et al., 2001). To investigate 
if apoptotic cell death could alter cytokine production from 
iNKT cells, two different experiments were performed com-
paring splenocytes from WT mice that were injected or not 
iNKT cells sense apoptotic cell death and alter their 
cytokine producing profile
We next turned our focus to the iNKT cell response to 
injected apoptotic cells, to examine if the phenotype in 
the iNKT/ mice could be supported. Because we have 
previously  defined  involvement  by  splenic  B  cells  in  this 
model (Wermeling et al., 2007), and established that these 
B cells express high levels of CD1d, we focused on the splenic 
iNKT cell population in WT mice. Interestingly, splenic 
iNKT cells up-regulated the activation marker CD69 after a 
Figure 2.  iNKT cells rapidly sense apoptotic cell death and alter their cytokine profile. (A) Plot showing CD69 expression on viable splenic B cells 
and iNKT cells 5 d after i.v. injection of apoptotic cells or control. (B) Data from supernatants of splenocyte cultures prepared from mice 5 d after injection of 
apoptotic cells and stimulated with GalCer for 72 h. IFN- and IL-10 measured by ELISA. (C) Intracellular IFN- FACS data of splenic CD4+ iNKT and NK cells 
5 d after injection of apoptotic cells and ex vivo stimulation with PMA/ionomycin/Brefeldin A. (D) IFN- measurement of WT and J18/ splenocytes stimu-
lated with GalCer as in B, but comparing cells from mice injected with apoptotic cells four times, instead of once. (E) Viable B and T cells in cultures from  
D measured using propidium iodine exclusion with FACS. Results are expressed as individual mice and mean in A (n = 6) and C (n = 3–16) and mean ± SEM 
in B (n = 6), D (n = 7), and E (n = 4–7). n.s. = not significant. *, P < 0.05; **, P < 0.01. Data are representative of at least two independent experiments.JEM VOL. 207, May 10, 2010  947
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A CD1d-dependent peripheral tolerance checkpoint  
for GC B cells
The results suggested that iNKT cell interaction with CD1d 
on autoreactive B cells could directly limit their autoantibody 
with apoptotic cells. These experiments were initially per-
formed 5 d after a single injection of apoptotic cells to match 
when the B cell compartment was evaluated by measuring 
antibody levels. First, we used GalCer to selectively activate 
iNKT cells in splenocyte cultures and measured secreted cyto-
kines. Interestingly, GalCer was not able to induce IFN- 
production in splenocyte cultures from injected mice, in contrast 
to noninjected, instead a significant IL-10 production was seen 
(Fig. 2 B). Second, using intracellular FACS we found a signifi-
cant reduction in IFN- producing iNKT cells after ex vivo 
stimulation with PMA and Ionomycin. In contrast to NK cells 
and CD4+ T cells that increased their IFN- producing abil-
ity after the injection (Fig. 2 C and Fig. S3). Furthermore, 
after four injections of apoptotic cells the addition of GalCer 
strongly decreased the spontaneous IFN- production seen 
in splenocyte cultures (Fig. 2 D). Interestingly, the activation 
of iNKT cells in these cultures also led to a decreased   
B cell (but not T cell) survival (Fig. 2 E). We conclude that 
iNKT cells rapidly detect apoptotic cell death, which alters 
their  cytokine  producing  ability  toward  a  seemingly  less 
pro-inflammatory signature and that their activation could 
affect B cell survival. Together this supports the notion of a 
regulatory role for iNKT cells in the model.
Adoptive transfer reveals a direct role for CD1d on B cells 
limiting autoreactive activation
CD1d is expressed on several cell populations, including DCs, 
which could have a role in regulating the autoreactive response 
to an increased load of apoptotic cells. To determine whether 
iNKT cells directly interact with autoreactive CD1d-expressing 
B cells, adoptive transfer experiments were performed. Puri-
fied B cells from WT or CD1d/ mice were transferred to 
CD19/ recipient mice and the autoreactive response to in-
jected apoptotic cells was followed (Fig. 3 A). CD19/ mice 
have a severe B cell defect with nonresponsiveness in the 
model used, as well as other models; the mice also display the 
selective absence of MZB and B1 B cells, but normal iNKT 
cell levels (Rickert et al., 1995; unpublished data). The ex-
pression of CD19 can also easily be used to track the trans-
ferred B cells. The injections of apoptotic cells in recipients 
of WT or CD1d/ B cells led to a significantly higher IgM 
and IgG3 anti-DNA response from the CD1d/ B cells 
(Fig. 3 B). Interestingly, a higher proportion of the remaining 
transferred cells in the spleen had a MZB phenotype in the 
recipients of CD1d/ B cells after four injections of apo-
ptotic cells, suggesting an increased survival in the absence of 
CD1d expression (Fig. S4).
Additionally, immunofluorescence examination of spleen 
sections, after four injections with apoptotic cells, showed 
transferred cells (CD19+), in the recipient of CD1d/ B cells in 
GCs (Fig. 3 C). This was also seen when quantifying splenic 
GCs with histology from WT and CD1d/ mice injected 
four times with apoptotic cells (Fig. 3 D). Thus, we conclude 
that CD1d on autoreactive B cells can directly regulate their 
activation to apoptotic cell–derived antigens; the data sug-
gests that this occurs before GC entry.
Figure 3.  Increased autoantibody production from adoptively trans-
ferred splenic CD1d/ B cells. (A) Schematic illustration of the transfer 
of purified B cells from WT or CD1d/ mice to a CD19/ recipient,  
followed by four injections of apoptotic cells. (B) IgM and IgG3 anti-DNA 
measured by ELISA in apoptotic cell–injected recipients and control mice. 
(C) Representative splenic immunofluorescence image from transferred WT  
B cells and CD1d/ B cells at day 26. Transferred cells are visualized by 
their CD19 and B220 expression in contrast to the recipient B cells 
(CD19/) only expressing B220. GCs are visualized by GL7 staining and 
indicated by arrows. (D) Representative splenic GC histology of WT and 
CD1d/ mice injected four times with apoptotic cells. Bars: (C) 150 µm; 
(D) 300 µm. Results are shown as mean ± SEM in B (n = 6–12 for recipient 
groups; n = 4 for CD19/ without transfer) and D (n = 6). *, P < 0.05. Data 
are representative of at least two independent experiments.948 iNKT cells in autoreactive B cell activation | Wermeling et al.
(Fig. 4, B–D), which was even more pronounced after four 
injections (Fig. 4 E). To control whether the increased GC 
phenotype was a general phenomenon in the absence of 
iNKT cells, two experiments were performed. First, we ana-
lyzed GC B cells in Peyer’s patches (a location with high lev-
els of spontaneous GC B cells, because of the influence of the 
gut microbiota) in mixed BM chimeras created as described 
above (Fig. 4 F). Second, we examined the levels of splenic 
GC  B  cells  after  two  injections  of 
NP-OVA (as described in Fig. 1 G) in 
WT and CD1d/ mice (Fig. 4 G). 
No difference was seen between WT 
and CD1d/ mice in these two ex-
periments, showing that CD1d does 
not have a general effect on the levels 
of GC B cells. Furthermore, examin-
ing CD1d expression on B cells in 
WT mice injected with apoptotic cells 
showed an impressive down-regulation 
of  CD1d  on  the  triggered  GC   
B cells and an up-regulation on MZB 
cells (Fig. 4 H). We conclude that a 
CD1d-dependent peripheral tolerance 
checkpoint exists, which regulates the 
activation of autoreactive B cells against 
apoptotic  material,  and  that  this 
checkpoint most probably is located 
before the GC entry. Interestingly, a 
production. To more carefully investigate the GC phenotype, 
mixed BM chimeric mice were created using WT and CD1d/ 
BM and subsequently injected with apoptotic cells (Fig. 4 A). 
The B cells in the chimeric mice do, side by side, experience 
the same conditions during the injections, allowing for di-
rect examination of the role of CD1d on them. After only 
two  injections  of  apoptotic  cells,  a  significantly  higher 
proportion of the CD1d/ B cells had a GC phenotype   
Figure 4.  A CD1d-dependent peripheral 
tolerance checkpoint limits GC B cell  
levels. (A) Schematic illustration of the  
experimental setup comparing GC entry after 
injections of apoptotic cells in mixed WT and 
CD1d/ BM chimeric mice. (B and C) Repre-
sentative FACS gating of splenic GC B cells 
(GL7hi and CD95hi) from noninjected and  
injected mice of the indicated genetic back-
ground (WT = CD45.1+ and CD1d/ = 
CD45.1). Data shown as percentage of  
B cells with GC phenotype of total B cells 
with the indicated genotype after two (D) or 
four (E) injections. Lines connect the CD1d/ 
and the WT populations in individual mice.  
n = 3–10. (F) Examination of the role of CD1d 
expression on GC B cell levels in Peyer’s 
patches in a mixed BM chimera, as in B and C.  
(G) Splenic GC B cells in WT and CD1d/ 
after the second injection of NP-OVA (see  
Fig. 1 G for protocol) measured by FACS.  
(H) FACS staining of CD1d expression on WT 
splenocytes injected four times with apo-
ptotic cells. FoB, MZB, and GC cells gated as in   
Fig. 1 E and Fig. 4 C. Results are shown as 
individual mice and mean in F (n = 4) and H 
(n = 3–7) and mean ± SEM in G (n = 4–6).  
*, P < 0.05; **, P < 0.01. Data are representative 
of two independent experiments.JEM VOL. 207, May 10, 2010  949
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similar B cell activation checkpoint has been described to be 
defective in SLE patients (Cappione et al., 2005).
Reduced numbers of iNKT cells is sufficient to see increased 
autoreactive B cell activation, and this can be rescued  
by transfer of iNKT cells to deficient mice
Examination of mice with total absence of iNKT cells in dis-
ease models can give insights in the role of this cell popula-
tion. One can, however, argue that the translation to human 
disease can be problematic, as the link to disease in e.g., SLE 
patients is to a reduced level of iNKT cells, not to complete 
absence. We therefore made mice heterozygous for the J18 
deletion (i.e., J18+/) and examined their response to injec-
tions of apoptotic cells. Deletion of one J18 allele resulted 
in a reduction of almost exactly 50% of the peripheral iNKT 
population (Fig. 5 A). This reduction was somewhat unex-
pectedly sufficient to change the phenotype to that of the 
J18/ mice, with significantly increased IgG anti-DNA 
levels and splenic germinal center B cell levels (Fig. 5, B and C). 
This finding supports that a reduction in iNKT cells is 
enough to affect disease parameters in lupus patients. As we 
propose that the B cells and the iNKT cells interact as the   
activated B cells migrate toward the GC, the reduced iNKT 
cell population might not be sufficient to interact with the   
B cells during the limited period before the B cell down- 
regulate CD1d.
To further establish the potential role for iNKT cells as a 
therapeutic target in SLE patients, we performed a transfer of 
iNKT cells to J18/ mice and observed whether this could 
ameliorate the autoreactive response to injections of apoptotic 
cells (Fig. 5 D). The transferred population was enriched for 
untouched iNKT by purification from V14-C/ mice 
(Lehuen et al., 1998). These mice express a transgenic TCR 
chain used by iNKT cells (V14-J18) on a TCR chain–
deficient background. Repopulation of the iNKT cell popu-
lation showed significant effects on all the autoreactive   
B cell activation parameters previously studied, including anti-
DNA response (Fig. 5 E) and both the size of the GC   
Figure 5.  Reduced levels of iNKT cells are sufficient to see  
increased autoreactive B cell activation to injected apoptotic cells, 
and this can be rescued by transferring iNKT cells. (A) FACS analysis 
of the splenic iNKT cell population (TCR+ and GalCer loaded CD1d-
dimer+) in WT, J18+/ and J18/ mice. (B) IgG anti-DNA response 
and (C) analysis of splenic and lymph node GCs after four injections of 
apoptotic cells in mice described in (A). (D) Schematic illustration of the 
iNKT cell transfer to a J18/ recipient followed by four injections of 
apoptotic cells. (E) IgG3 anti-DNA response in mice described in (D) 
measured by ELISA. (F) Quantification of splenic GC B cells with FACS 
day 26. (G) Representative histology of splenic GCs (GL7+, indicated by 
arrows) day 26. Bars, 300 µm. Results are shown as individual mice and 
mean in A (n = 3), C (n = 1–7), and F (n = 7) and mean ± SEM in B  
(n = 7) and E (n = 7). *, P < 0.05; **, P < 0.01. Data are representative of 
two independent experiments (A–C) or pooled from two independent 
experiments (D–G).
Figure 6.  Schematic illustration describing that iNKT cells  
limit the levels of autoreactive GC B cells, and thereby autoanti-
body production in response to an increased load of circulating  
apoptotic cells.950 iNKT cells in autoreactive B cell activation | Wermeling et al.
apoptotic cells weekly and bled for 4 wk. TNP-Ficoll and NP-OVA (Bio-
search Technologies, Inc.) were injected i.v. (20 µg/mouse) in PBS and i.p. 
(50 µg/mouse) in alum (Thermo Fisher Scientific), respectively.
Antibody levels against DNA and TNP-Ficoll were measured with ELISA 
as previously described (Wermeling et al., 2007) and reactivity against the 
injected NP-OVA was measured using NP-BSA (Biosearch Technologies, 
Inc.) coated ELISA plates (Thermo Fisher Scientific). Reactivity against PC 
was measured with PC-BSA (a gift from Athera Biotechnologies AB) and 
cardiolipin reactivity was measured with cardiolipin purchased from Sigma-
Aldrich as described in (Delgado Alves et al., 2003) using standard ELISA 
techniques and secondary reagents anti-IgG/IgG3/IgM-AP (SouthernBio-
tech). IL-10 and IFN- were measured in supernatants following the sug-
gested protocol (MabTech).
Adoptive transfer and BM chimeras. Naive splenic B cells were isolated 
from WT and CD1d/ mice using CD43, NK1.1, and CD11c microbeads 
(Miltenyi Biotec). Naive B cells were collected as the negative population 
and purity was confirmed with FACS. 3 × 107 purified B cells were injected 
i.v. in recipient CD19/ mice, and the next day apoptotic cell injections 
started. Untouched iNKT cells were enriched from the liver and spleen   
of V14-C/ mice (Lehuen et al., 1998) using established methods   
(Bezbradica et al., 2006), i.e., depletion of B220+, CD8+, CD11c+, and 
CD11b+ cells using microbeads (Miltenyi Biotec). This isolation technique 
provides mainly iNKT cells and some CD4+ T cells (Fig. S6). Approxi-
mately 0.8 × 106 untouched viable iNKT cells were transferred to each 
recipient and apoptotic cell injections started the following day.
CD19/ mice were lethally irradiated (900 rad) and reconstituted i.v. 
with 106 mixed BM cells from CD1d/ (CD45.2+) and C57BL/6-CD45.1 
mice. 7 wk after BM transfer, the mice were sacrificed and analyzed for chime-
rism with FACS or injected with apoptotic cells as described above.
FACS. Single-cell suspensions of organs were prepared and erythrocytes 
were lysed. Nonspecific labeling was blocked with anti-CD16/32 (Fc Block) 
before specific labeling. Samples were analyzed using a FACSCalibur or   
a FACSAria (BD). iNKT cells were labeled using GalCer (KRN7000;   
Larodan Fine Chemicals) loaded CD1d-dimerX as suggested by the manu-
facturer (BD), and defined as viable (DAPI), B220, TCR+ CD1d:GalCer+ 
lymphocytes. For intracellular cytokine staining, single-cell suspensions of 
splenocytes were cultured in complete medium for 5 h in the presence of 
PMA (50 ng/ml), ionomycin (500 ng/ml; both from Sigma-Aldrich), and 
Brefeldin A (BioLegend). In Fig. S2, the stimulation protocol was adopted 
from a previous study (Yanaba et al., 2008), also including LPS (10 µg/ml; 
Sigma-Aldrich). Extracellular proteins were then labeled and after several 
washing steps, fixation and permeabilization (buffers from BioLegend) 
followed. Intracellular IFN- was labeled (antibody clone XMG1.2) and 
samples were analyzed on a FACSAria (BD). LIVE/DEAD was used to   
remove dead cells when intracellular staining was performed before the 
fixation step, as suggested by the manufacturer (Invitrogen). All FACS plots 
show log10 fluorescence.
Ex vivo stimulation and histology. Cytokine and antibody release was 
measured from splenocyte cultures after 72 h in complete media with GalCer 
(100 ng/ml) or 10 µg/ml LPS (Sigma-Aldrich) stimulation. Immunohistology 
was performed as previously described (Wermeling et al., 2007). H&E staining 
was performed using standard protocol. Immune complex deposition in kid-
neys was quantified by three blinded observers and arbitrarily scored from 0–3 
dependent on the intensity and amount of the anti-IgG staining. Quantifica-
tion of GC was done by one blinded observer counting GC (GL7) staining and 
total amount of follicles (CD19+ cells surrounding TCR+ cells). More than 
20 follicles were counted on each sample, and a number corresponding to 
the amount of GCs per 10 follicles was calculated. Antibodies for FACS and 
histology were obtained from BD or BioLegend.
Statistical  analysis.  Data  were  compared  using  nonparametric  tests; 
Kruskal-Wallis test followed by Dunns post-test (Fig.1), Mann-Whitney test 
B cell population (Fig. 5 F) and the amount of GCs (Fig. 5 G 
and Fig. S5).
These data suggest the presence of an inhibitory iNKT–
CD1d+ B cell axis limiting autoreactive response to increased 
levels of apoptotic cells. The need for CD1d on B cells sug-
gests that the iNKT cell recognizes ligands presented in CD1d 
that, at the time, is interpreted as a signal to limit B cell acti-
vation. Explanations for this include presentation of inhibi-
tory ligands, or that the iNKT cell is affected by other factors, 
like TLR engagement or cytokines, to perceive the ligand as 
inhibitory. Several candidate lipid derivatives, relevant for this 
study, have been shown to be presented in CD1d context, 
e.g., the phospholipid phosphatidylcholine (PC) and its de-
rivative lyso-PC, which is released during apoptosis (Giabbai 
et al., 2005; Chang et al., 2008). Furthermore, lyso-PC– 
specific type II NKT cells have been identified and are ex-
panded in myeloma patients (Chang et al., 2008). However, 
it is not known if this population could be antiinflammatory, 
although the tumor-associated lipid derivative gangliotriaosyl-
ceramide has been confirmed to mediate immunosuppressive 
activity on iNKT cell activation (Sriram et al., 2002).
In conclusion, we suggest a model where iNKT cells are 
linked to the anti-inflammatory milieu created by apoptotic 
cell death. In response to dying cells they acquire an antiinflam-
matory phenotype and are able to limit activation of auto-
reactive B cells (Fig. 6). The exact mechanism involved is not 
completely clear, hampered by the lack of knowledge about 
the precise nature of the B cell activation, but seems to in-
volve both effects on cytokines and direct B cell survival. In 
the absence of iNKT cells, or CD1d expression on B cells, 
the balance in the response to an increased load of apoptotic 
cells is shifted. This is manifested as increased autoreactive   
B cell activation with increased GC B cell levels and auto-
antibody production. SLE is a multigenetic disease and sub-
groups displaying different symptoms can readily be found in 
the patient group (Kotzin, 1996). Our data indicate that 
iNKT cells could have an important protective role in pa-
tients where autoreactivity is driven by defects in apoptotic 
cell homeostasis, and that this could be modulated by increasing 
the iNKT cell numbers.
MATERIALS AND METHODS
Mice. CD1d/ (Chen et al., 1997) and J18/ (Cui et al., 1997) mice   
on C57BL/6 background were provided by M. Johansson and P. Höglund 
(Karolinska  Institutet,  Stockholm,  Sweden).  iNKT  transgenic  V14-C/ 
mice (Lehuen et al., 1998) were provided by A. Lehuen (INSERM U561, Paris, 
France). CD19/ mice (Rickert et al., 1995) were kindly provided by   
N. Lycke (Göteborg University, Göteborg, Sweden). C57BL/6 mice congenic 
for CD45.1 were obtained from Charles River Laboratories. Age- and 
sex- matched mice were used in all experiments, aged 6–12 wk. Animals were 
kept and bred under pathogen-free conditions and experiments were approved 
by the local ethical committee (the North Stockholm district court).
Injections, antigens, and ELISA. Apoptosis was induced in syngenic 
thymocytes with dexamethasone (Sigma-Aldrich) as previously described 
(Wermeling et al., 2007), with the modification that thymi were collected 
from CD1d-deficient mice. This was to eliminate the transfer of apoptotic 
iNKT cells and CD1d-expressing cells. Mice were injected i.v. with 107 JEM VOL. 207, May 10, 2010  951
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